Gonadorelin vs MK-677 (Ibutamoren)
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Gonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profileMK-677 (Ibutamoren)
Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.
Full profile| Gonadorelin | MK-677 (Ibutamoren) | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse | Ibutamoren, Nutrobal, MK677, L-163,191 |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, 2–3x per week subcutaneous | 10mg–50mg mg, once daily oral |
| Administration | Subcutaneous injection, Intranasal (pulsatile delivery) | Oral (capsule/liquid) |
| Key side effects | Injection site reactions, Headache, Nausea, Flushing | Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); MK-677 (Ibutamoren) — Oral (capsule/liquid).
- Dosing units differ: Gonadorelin is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
- Frequency: Gonadorelin is typically 2–3x per week subcutaneous; MK-677 (Ibutamoren) is once daily oral.
How each works
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
MK-677 (Ibutamoren)
MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.